MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Codexis Inc

Fermé

SecteurSoins de santé

2.39 -2.05

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.37

Max

2.5

Chiffres clés

By Trading Economics

Revenu

-10M

-21M

Ventes

-14M

7.5M

Marge bénéficiaire

-274.268

Employés

188

EBITDA

-11M

-20M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+140.98% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-17M

202M

Ouverture précédente

4.44

Clôture précédente

2.39

Sentiment de l'Actualité

By Acuity

19%

81%

26 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Codexis Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juil. 2025, 23:09 UTC

Résultats

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 juil. 2025, 19:16 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 juil. 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 juil. 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 juil. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

James Hardie Completes Acquisition of AZEK

1 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 juil. 2025, 20:24 UTC

Résultats

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 juil. 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 juil. 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 juil. 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 juil. 2025, 19:01 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 juil. 2025, 18:41 UTC

Acquisitions, Fusions, Rachats

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 juil. 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 juil. 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 juil. 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 juil. 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 juil. 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 juil. 2025, 17:01 UTC

Acquisitions, Fusions, Rachats

Danone Completed Acquisition of Majority Stake in Kate Farms

1 juil. 2025, 16:55 UTC

Résultats

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 juil. 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 juil. 2025, 16:25 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 15:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 juil. 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 juil. 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparaison

Variation de prix

Codexis Inc prévision

Objectif de Prix

By TipRanks

140.98% hausse

Prévisions sur 12 Mois

Moyen 5.88 USD  140.98%

Haut 11 USD

Bas 3 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

4

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.25 / 2.53Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

26 / 380Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.